First Horizon Advisors Inc. Has $604,000 Stock Holdings in Stryker Co. (NYSE:SYK)

First Horizon Advisors Inc. trimmed its position in Stryker Co. (NYSE:SYK) by 4.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,017 shares of the medical technology company’s stock after selling 104 shares during the quarter. First Horizon Advisors Inc.’s holdings in Stryker were worth $604,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of SYK. Sage Mountain Advisors LLC increased its stake in shares of Stryker by 5.5% in the third quarter. Sage Mountain Advisors LLC now owns 1,272 shares of the medical technology company’s stock worth $348,000 after purchasing an additional 66 shares during the period. Everhart Financial Group Inc. increased its position in Stryker by 4.4% in the 3rd quarter. Everhart Financial Group Inc. now owns 2,328 shares of the medical technology company’s stock worth $636,000 after buying an additional 98 shares during the period. Hixon Zuercher LLC lifted its holdings in shares of Stryker by 2.1% during the third quarter. Hixon Zuercher LLC now owns 22,323 shares of the medical technology company’s stock worth $6,100,000 after buying an additional 450 shares during the last quarter. Lindbrook Capital LLC boosted its position in shares of Stryker by 5.1% in the third quarter. Lindbrook Capital LLC now owns 1,007 shares of the medical technology company’s stock valued at $275,000 after acquiring an additional 49 shares during the period. Finally, Verdence Capital Advisors LLC grew its stake in shares of Stryker by 9.2% in the third quarter. Verdence Capital Advisors LLC now owns 1,017 shares of the medical technology company’s stock worth $278,000 after acquiring an additional 86 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the transaction, the director now owns 3,755,128 shares in the company, valued at approximately $1,287,633,391.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the sale, the director now directly owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on SYK shares. UBS Group upped their target price on shares of Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a research note on Wednesday. Wells Fargo & Company increased their target price on shares of Stryker from $364.00 to $381.00 and gave the company an “overweight” rating in a research note on Wednesday. Robert W. Baird boosted their price target on Stryker from $367.00 to $378.00 and gave the company an “outperform” rating in a research note on Wednesday. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target for the company in a report on Wednesday, January 31st. Finally, Barclays boosted their price objective on Stryker from $372.00 to $376.00 and gave the company an “overweight” rating in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $365.94.

Stryker Trading Up 0.6 %

Shares of Stryker stock opened at $328.45 on Friday. The stock has a market capitalization of $125.12 billion, a P/E ratio of 37.49, a price-to-earnings-growth ratio of 2.56 and a beta of 0.91. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The company has a quick ratio of 0.97, a current ratio of 1.71 and a debt-to-equity ratio of 0.56. The company has a 50-day simple moving average of $346.99 and a 200 day simple moving average of $317.29.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.36 by $0.14. The company had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. Stryker’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.14 earnings per share. Research analysts expect that Stryker Co. will post 11.94 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 0.97%. The ex-dividend date was Wednesday, March 27th. Stryker’s payout ratio is presently 36.53%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.